P08.43 Bevacizumab discontinuation and bevacizumab re-challenge in glioblastoma patients.
about
P08.43 Bevacizumab discontinuation and bevacizumab re-challenge in glioblastoma patients.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
P08.43 Bevacizumab discontinuation and bevacizumab re-challenge in glioblastoma patients.
@en
P08.43 Bevacizumab discontinuation and bevacizumab re-challenge in glioblastoma patients.
@nl
type
label
P08.43 Bevacizumab discontinuation and bevacizumab re-challenge in glioblastoma patients.
@en
P08.43 Bevacizumab discontinuation and bevacizumab re-challenge in glioblastoma patients.
@nl
prefLabel
P08.43 Bevacizumab discontinuation and bevacizumab re-challenge in glioblastoma patients.
@en
P08.43 Bevacizumab discontinuation and bevacizumab re-challenge in glioblastoma patients.
@nl
P2093
P356
P1433
P1476
P08.43 Bevacizumab discontinuation and bevacizumab re-challenge in glioblastoma patients
@en
P2093
A. D’Hombres
B. Joubert
E. Jouanneau
J. Guyotat
J. Honnorat
S. Cartalat-Carel
P304
P356
10.1093/NEUONC/NOW188.176
P433
P50
P577
2016-09-21T00:00:00Z